Platelet rich plasma for treatment of osteoarthritis

Malaysian Health Technology Assessment (MaHTAS)
Record ID 32016000506
English
Authors' objectives: To assess the efficacy, safety and cost-effectiveness of platelet rich plasma for the treatment of osteoarthritis.
Authors' recommendations: Two systematic reviews, two randomised controlled trials and a non-randomised controlled trial were included in this review. There was insufficient but good level of evidence to support the effectiveness of PRP for the treatment of osteoarthritis. The longest outcome data available was only for 24 months in a study and revealed that the median beneficial results was nine months. Most of the studies available were case series. Studies that have comparisons, used hyaluronic acid as control. In certain countries such as the United Kingdom, intra-articular hyaluronic acid injections are not recommended for the treatment of osteoarthritis. The short term evidence showed that PRP may be beneficial for young (<50 years old) patients with early OA and not overweight or obese. However, the evidence is limited. In terms of safety, no major complications were reported in patients treated with PRP.
Details
Project Status: Completed
Year Published: 2013
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Malaysia
MeSH Terms
  • Humans
  • Osteoarthritis, Knee
  • Platelet-Rich Plasma
Contact
Organisation Name: Malaysian Health Technology Assessment
Contact Address: Malaysian Health Technology Assessment Section, Ministry of Health Malaysia, Federal Government Administrative Centre, Level 4, Block E1, Parcel E, 62590 Putrajaya Malaysia Tel: +603 8883 1229
Contact Name: htamalaysia@moh.gov.my
Contact Email: htamalaysia@moh.gov.my
Copyright: Malaysian Health Technology Assessment (MaHTAS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.